223 related articles for article (PubMed ID: 29052245)
1. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life.
Dunn Galvin A; McMahon S; Ponsonby AL; Hsiao KC; Tang MLK;
Allergy; 2018 Mar; 73(3):560-568. PubMed ID: 29052245
[TBL] [Abstract][Full Text] [Related]
2. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
3. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
4. Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).
Chebar Lozinsky A; Loke P; Orsini F; O'Sullivan M; L Prescott S; Gold MS; Quinn P; DunnGalvin A; Lk Tang M;
BMJ Open; 2020 Sep; 10(9):e035871. PubMed ID: 32912942
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
6. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial.
Hsiao KC; Ponsonby AL; Axelrad C; Pitkin S; Tang MLK;
Lancet Child Adolesc Health; 2017 Oct; 1(2):97-105. PubMed ID: 30169215
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of probiotic peanut oral immunotherapy (PPOIT) versus placebo in Australian children with peanut allergy alongside a randomised trial.
Huang L; Dalziel K; Lloyd M; Loke P; Lozinsky AC; Tang M
BMJ Open; 2023 Dec; 13(12):e075521. PubMed ID: 38072489
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy (PPOIT) in children with peanut allergy.
Hsiao KC; Ponsonby AL; Ashley S; Lee CYY; Jindal L; ; ; Tang MLK
Clin Exp Allergy; 2022 Apr; ():. PubMed ID: 35403286
[TBL] [Abstract][Full Text] [Related]
10. Food allergy-related quality of life after double-blind, placebo-controlled food challenges in adults, adolescents, and children.
van der Velde JL; Flokstra-de Blok BM; de Groot H; Oude-Elberink JN; Kerkhof M; Duiverman EJ; Dubois AE
J Allergy Clin Immunol; 2012 Nov; 130(5):1136-1143.e2. PubMed ID: 22835403
[TBL] [Abstract][Full Text] [Related]
11. Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study).
Loke P; Chebar Lozinsky A; Orsini F; Wong LS; Leung AS; Tham EH; Lopata AL; Shek LP; Tang ML;
BMJ Open; 2021 Jul; 11(7):e044331. PubMed ID: 34233966
[TBL] [Abstract][Full Text] [Related]
12. Interaction Between Baseline Participant Factors and Treatment Effects Following Peanut Oral Immunotherapy.
Lloyd M; Loke P; Ashley S; Lozinsky AC; Orsini F; O'Sullivan M; Gold M; Quinn P; Metcalfe J; Tang MLK
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):1019-1028.e2. PubMed ID: 38154554
[TBL] [Abstract][Full Text] [Related]
13. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
[TBL] [Abstract][Full Text] [Related]
14. Changes in patient quality of life during oral immunotherapy for food allergy.
Rigbi NE; Goldberg MR; Levy MB; Nachshon L; Golobov K; Elizur A
Allergy; 2017 Dec; 72(12):1883-1890. PubMed ID: 28542911
[TBL] [Abstract][Full Text] [Related]
15. No difference in health-related quality of life, after a food challenge with cashew nut in children participating in a clinical trial.
van der Valk JP; Gerth van Wijk R; Flokstra-de Blok BM; van der Velde JL; de Groot H; Wichers HJ; Dubois AE; de Jong NW
Pediatr Allergy Immunol; 2016 Dec; 27(8):812-817. PubMed ID: 27495003
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal validity and responsiveness of the Food Allergy Quality of Life Questionnaire - Parent Form in children 0-12 years following positive and negative food challenges.
DunnGalvin A; Cullinane C; Daly DA; Flokstra-de Blok BM; Dubois AE; Hourihane JO
Clin Exp Allergy; 2010 Mar; 40(3):476-85. PubMed ID: 20210816
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
Blumchen K; Trendelenburg V; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Roeder M; Rosenfeld L; Hartmann O; Niggemann B; Beyer K
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):479-491.e10. PubMed ID: 30423449
[TBL] [Abstract][Full Text] [Related]
18. Peanut allergy impact on productivity and quality of life (PAPRIQUA): Caregiver-reported psychosocial impact of peanut allergy on children.
Acaster S; Gallop K; de Vries J; Ryan R; Vereda A; Knibb RC
Clin Exp Allergy; 2020 Nov; 50(11):1249-1257. PubMed ID: 32866989
[TBL] [Abstract][Full Text] [Related]
19. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
Anagnostou K; Islam S; King Y; Foley L; Pasea L; Bond S; Palmer C; Deighton J; Ewan P; Clark A
Lancet; 2014 Apr; 383(9925):1297-1304. PubMed ID: 24485709
[TBL] [Abstract][Full Text] [Related]
20. Parents report better health-related quality of life for their food-allergic children than children themselves.
van der Velde JL; Flokstra-de Blok BM; Dunngalvin A; Hourihane JO; Duiverman EJ; Dubois AE
Clin Exp Allergy; 2011 Oct; 41(10):1431-9. PubMed ID: 21569128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
